scholarly journals A review of techniques for visualising soft tissue microstructure deformation and quantifying strain Ex Vivo

2018 ◽  
Vol 272 (3) ◽  
pp. 165-179 ◽  
Author(s):  
C.M. DISNEY ◽  
P.D. LEE ◽  
J.A. HOYLAND ◽  
M.J. SHERRATT ◽  
B.K. BAY
2022 ◽  
Vol 148 ◽  
pp. 106775
Author(s):  
Zhaojun Wang ◽  
Kun Feng ◽  
Fan Yang ◽  
Yansheng Liang ◽  
Xue Yun ◽  
...  

2021 ◽  
Author(s):  
K Moffitt ◽  
E Cheung ◽  
T Yeung ◽  
C Stamoulis ◽  
R Malley

A comprehensive understanding of how Staphylococcus aureus adapts to cause infections in humans can inform development of diagnostic, therapeutic, and preventive approaches. Expression analysis of clinical strain libraries depicts in vitro conditions that differ from those in human infection, but low bacterial burden and the requirement for reverse transcription or nucleic acid amplification complicate such analyses of bacteria causing human infection. We developed methods to evaluate the mRNA transcript signature of S. aureus in pediatric skin and soft tissue (SSTI) infections directly ex vivo. Abscess drainage from 47 healthy pediatric patients undergoing drainage of a soft tissue infection was collected, and RNA was extracted from samples from patients with microbiologically confirmed S. aureus abscesses (42% due to methicillin-resistant S. aureus, MRSA). Using the Nanostring platform and primers targeting S. aureus mRNA transcripts encoding surface-expressed or secreted proteins, we measured direct counts of 188 S. aureus mRNA transcripts in abscess drainage. We further evaluated this mRNA signature in murine models of S. aureus SSTI and nasal colonization where the kinetics of the transcriptome could be determined. Heat maps of the S. aureus mRNA signatures from pediatric abscesses demonstrated consistent per target expression across patients. While there was significant overlap with the profiles from murine SSTI and nasal colonization, important differences were noted, which can inform efforts to develop therapeutic and vaccine approaches.


2020 ◽  
Vol 142 (3) ◽  
Author(s):  
Charlotte A. Guertler ◽  
Ruth J. Okamoto ◽  
Jake A. Ireland ◽  
Christopher P. Pacia ◽  
Joel R. Garbow ◽  
...  

Abstract This paper describes a new method for estimating anisotropic mechanical properties of fibrous soft tissue by imaging shear waves induced by focused ultrasound (FUS) and analyzing their direction-dependent speeds. Fibrous materials with a single, dominant fiber direction may exhibit anisotropy in both shear and tensile moduli, reflecting differences in the response of the material when loads are applied in different directions. The speeds of shear waves in such materials depend on the propagation and polarization directions of the waves relative to the dominant fiber direction. In this study, shear waves were induced in muscle tissue (chicken breast) ex vivo by harmonically oscillating the amplitude of an ultrasound beam focused in a cylindrical tissue sample. The orientation of the fiber direction relative to the excitation direction was varied by rotating the sample. Magnetic resonance elastography (MRE) was used to visualize and measure the full 3D displacement field due to the ultrasound-induced shear waves. The phase gradient (PG) of radially propagating “slow” and “fast” shear waves provided local estimates of their respective wave speeds and directions. The equations for the speeds of these waves in an incompressible, transversely isotropic (TI), linear elastic material were fitted to measurements to estimate the shear and tensile moduli of the material. The combination of focused ultrasound and MR imaging allows noninvasive, but comprehensive, characterization of anisotropic soft tissue.


2020 ◽  
Vol 19 ◽  
pp. e83-e84
Author(s):  
M.E. Rodríguez Socarrás ◽  
S. Proietti ◽  
R. Luciano’ ◽  
F. Scarfo’ ◽  
G. Saitta ◽  
...  

2019 ◽  
Vol 24 (8) ◽  
pp. 2645-2652 ◽  
Author(s):  
Gaspare Palaia ◽  
Alessandra Impellizzeri ◽  
Gianluca Tenore ◽  
Federico Caporali ◽  
Paolo Visca ◽  
...  

2020 ◽  
Author(s):  
Silvia Proietti ◽  
Moises Elias Rodríguez-Socarrás ◽  
Brian Howard Eisner ◽  
Roberta Lucianò ◽  
Mario José Basulto Martinez ◽  
...  

2010 ◽  
Vol 75 (2) ◽  
pp. e124-e128 ◽  
Author(s):  
H. Zachrisson ◽  
E. Engström ◽  
J. Engvall ◽  
L. Wigström ◽  
Ö. Smedby ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10084-10084
Author(s):  
Jenny Kreahling ◽  
Damon R. Reed ◽  
Parastou Foroutan ◽  
Gary Martinez ◽  
Robert Gillies ◽  
...  

10084 Background: Sarcomas consist of more than 50 subtypes of mesenchymal tumors. Doxorubicin alone or in combination has been the primary therapy for treatment of sarcomas; however, the response rates are suboptimal in many of the more common adult subtypes of soft tissue sarcoma. Accordingly, new agents are needed for the treatment of this heterogeneous group of diseases. Wee1 is a critical component of the G2/M cell cycle checkpoint control and mediates cell cycle arrest by regulating the phosphorylation of CDC2. Methods: MK1775 treatment of multiple sarcoma preclinical models at clinically relevant concentrations leads to unscheduled entry into mitosis and initiation of apoptotic cell death. In our current study we have investigated the therapeutic efficacy of MK1775 in sarcoma cell lines, patient-derived tumor explants ex vivo and in vivo in a xenograft model of osteosarcoma both alone and in combination with gemcitabine. Results: In patient-derived bone and soft tissue sarcoma samples ex vivo treatments show MK1775 in combination with gemcitabine causes significant apoptotic cell death suggesting that this treatment may represent a novel approach in the treatment of sarcomas. The cytotoxic effect of Wee1 inhibition on sarcoma cells appears to be independent of p53 mutational status. Furthermore, in a patient-derived osteosarcoma xenograft mouse model we show the therapeutic efficacy of MK1775 in vivo by utilizing magnetic resonance imaging (MRI) and diffusion MRI methods. Our data shows MK1775 in combination with gemcitabine dramatically slows tumor growth, increases apoptotic cell death and increases CDC2 activity. Cell viability, a clinically established prognostic indicator of survival, was lowest with the combination and very low in animals treated with MK1775 alone. This was mainly due to increased mineralization of the tumors. Caspase-3 was increased in MK1775 treated animals by immunohistochemistry as well. Conclusions: These results together with the promising safety profile of MK1775 strongly suggest that this drug can be used as a potential therapeutic agent alone or in combination with gemcitabine in the treatment of both adult as well as pediatric sarcoma patients.


2007 ◽  
Vol 116 (11) ◽  
pp. 853-857 ◽  
Author(s):  
James A. Burns ◽  
James B. Kobler ◽  
James T. Heaton ◽  
Gerardo Lopez-Guerra ◽  
R. Rox Anderson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document